Emergent Biosolutions Inc

1. 1

   Election of Class II Directors

   ManagementBoard: FOR

   Elect Sujata Dayal, John Fowler, Jr., Zsolt Harsanyi, Ph.D., and Joseph Papa as Class II directors to hold office until the 2029 annual meeting.

2. 2

   Ratification of Appointment of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify the appointment of Ernst & Young LLP as Emergent’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

3. 3

   Advisory Vote to Approve 2025 Compensation of Named Executive Officers (Say-on-Pay

   ManagementBoard: FOR

   Non-binding advisory vote to approve the 2025 compensation of the company’s named executive officers as disclosed in the proxy statement.

   More detail

   This proposal asks shareholders to cast a non-binding advisory vote approving the Company’s 2025 compensation of its named executive officers (NEOs) as disclosed in the proxy statement, including the Compensation Discussion and Analysis, tables, and related narrative. Management seeks this advisory approval to confirm alignment between executive pay and stockholder expectations and to solicit investor feedback on pay practices, consistent with long-standing say-on-pay practice under Section 14A of the Exchange Act. The Company frames its 2025 program around pay-for-performance principles, with a mix of base salary, annual cash incentives, and equity awards (options, PSUs or RSUs) tied to corporate and individual metrics and multi-year performance goals; the Board emphasizes that compensation is intended to attract, retain and motivate leaders during the company’s turnaround. Notably, the Compensation Committee exercised discretion in certifying certain PSU outcomes (e.g., a 25% payout for the 2023‑2025 PSUs despite results slightly below threshold) to reflect strategic progress, retention considerations and external factors—an element likely to be scrutinized by governance-focused investors. The Board recommends a vote FOR, stating that the program is competitive, has robust governance (independent committee, advisor review, clawback policy and stock ownership guidelines) and that the Compensation Committee will consider the advisory vote result in future decisions. Because the vote is advisory, it does not change compensation contract terms but signals investor sentiment that the Compensation Committee and Board will weigh when setting future pay and plan design. When evaluating the merits, analysts should weigh the company’s recent financial improvement (net income and adjusted EBITDA recovery in 2025), the demonstrated reliance on discretion in PSU payouts, the contingent nature of some 2026 awards on shareholder approval of the Plan amendment, and the fact that the Board ties equity awards to multi-year strategic objectives—factors that affect pay-for-performance alignment and retention risk. Overall, the resolution is a governance checkpoint intended to validate or provide feedback on the Board’s approach to executive compensation amid a multi-year turnaround and constrained share pool dynamics.

4. 4

   Approval of Amendment to Amended and Restated Stock Incentive Plan to Increase Shares Available for Awards

   ManagementBoard: FOR

   Approve an amendment to the Emergent BioSolutions Inc. Amended and Restated Stock Incentive Plan to add 5,000,000 shares to the plan reserve for issuance of awards.

   More detail

   This proposal asks shareholders to approve a 5,000,000-share increase to the Company’s Amended and Restated Stock Incentive Plan reserve to enable continued equity grant activity for employees, executives and non-employee directors. Management argues the increase is necessary because the existing share pool is effectively depleted given recent grants and outstanding full-value awards and options, and because the Company needs equity to attract, retain and motivate talent critical to executing its multi-year turnaround and growth plans. The filing discloses that the Board already granted contingent RSUs and PSUs in March 2026 that are subject to shareholder approval — approximately 2,043,910 shares underlying contingent awards (1,668,493 contingent RSUs and 375,417 contingent PSUs) — and that these contingent awards will be forfeited if the amendment is not approved, creating immediate operational stakes for approval. The Company quantifies the expected dilution and overhang — estimating the additional reserve would represent roughly a 9% potential dilution if fully issued and noting a total overhang of ~24% on a fully diluted basis (21% excluding underwater options) — and explains that failure to approve would force reliance on cash incentives, potentially impairing cash flexibility and competitiveness. The Board frames the amendment as supporting a return to performance-based grants (PSUs) and broader compensation practices aligned with pay-for-performance, while preserving anti-dilution and governance protections (no liberal recycling, no repricing without shareholder approval, double-trigger change-in-control vesting, director compensation caps). From an investor-analysis perspective, key considerations include the modest one-year runway the increase is intended to provide, the substantial existing outstanding awards and contingent grants, the use of full-value conversion multipliers historically, current share price and underwater option profile, and the dilution trade-off versus retention and performance alignment benefits. The Board recommends a vote FOR, emphasizing that the amendment is critical to execute strategic priorities, preserve equity-based incentive levers, and avoid short-term cash payouts that could hinder reinvestment; however, shareholders should weigh dilution, burn-rate assumptions, the Company’s historical share usage, and whether governance protections and disclosure are sufficient to limit unnecessary dilution.

Upcoming shareholder meetings at Emergent Biosolutions Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Emergent Biosolutions Inc 2026 annual meeting?

Emergent Biosolutions Inc (EBS) holds its 2026 annual shareholder meeting on Wednesday, April 29, 2026.

What is the record date for the Emergent Biosolutions Inc 2026 meeting?

The record date for the Emergent Biosolutions Inc 2026 meeting is Friday, March 6, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Emergent Biosolutions Inc's 2026 meeting?

The board is presenting 4 director nominees at the Emergent Biosolutions Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Emergent Biosolutions Inc 2026 meeting?

Shareholders will vote on 4 proposals at the Emergent Biosolutions Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.